Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Garth D. Nelson"'
Autor:
Tina J. Hieken, Garth D. Nelson, Thomas J. Flotte, Eric P. Grewal, Jun Chen, Robert R. McWilliams, Lisa A. Kottschade, Lu Yang, Evidio Domingo-Musibay, Roxana S. Dronca, Yiyi Yan, Svetomir N. Markovic, Anastasios Dimou, Heather N. Montane, Courtney L. Erskine, Mara A. Piltin, Daniel L. Price, Samir S. Khariwala, Jane Hui, Carrie A. Strand, Susan M. Harrington, Vera J. Suman, Haidong Dong, Matthew S. Block
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and dri
Externí odkaz:
https://doaj.org/article/6734662876464a8cb916380502e32069
Autor:
Steven R. Alberts, Daniel J. Sargent, Garth D. Nelson, Richard M. Goldberg, Stephen N. Thibodeau, Thomas C. Smyrk, Harry H. Yoon, Michelle R. Mahoney, Frank A. Sinicrope
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas.Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (exo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3723405e4e923dcadabc0af10aaaaf7b
https://doi.org/10.1158/1078-0432.c.6524849.v1
https://doi.org/10.1158/1078-0432.c.6524849.v1
Autor:
Steven R. Alberts, Daniel J. Sargent, Garth D. Nelson, Richard M. Goldberg, Stephen N. Thibodeau, Thomas C. Smyrk, Harry H. Yoon, Michelle R. Mahoney, Frank A. Sinicrope
Supplemental Table 1. Univariate Cox Proportional Hazards Regression Models for Clinical Factors and Biomarkers (TTR, DFS, and OS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf3021cadf1006b5b68776493f7cd72
https://doi.org/10.1158/1078-0432.22461659
https://doi.org/10.1158/1078-0432.22461659
Autor:
Frank A. Sinicrope, Daniel J. Sargent, Richard M. Goldberg, Stephen N. Thibodeau, Suresh G. Nair, Garth D. Nelson, Michelle R. Mahoney, Steven R. Alberts, Qian Shi, David Tougeron, Harry H. Yoon
Purpose: We examined the prognostic impact of specific KRAS mutations in patients with stage III colon adenocarcinoma receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF–wild-type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9208296a8956c4578543ede96ba27a60
https://doi.org/10.1158/1078-0432.c.6522842
https://doi.org/10.1158/1078-0432.c.6522842
Autor:
Frank A. Sinicrope, Daniel J. Sargent, Richard M. Goldberg, Stephen N. Thibodeau, Suresh G. Nair, Garth D. Nelson, Michelle R. Mahoney, Steven R. Alberts, Qian Shi, David Tougeron, Harry H. Yoon
PDF file - 108KB, Predictive value of specific KRAS mutations in patients with BRAF-wild type resected stage III colon cancer treated with adjuvant FOLFOX chemotherapy with vs without cetuximab. Unadjusted hazard ratios (HR) for disease-free survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b4763c88758e8f9e5682efd0996687
https://doi.org/10.1158/1078-0432.22454813.v1
https://doi.org/10.1158/1078-0432.22454813.v1
Autor:
Frank A. Sinicrope, Daniel J. Sargent, Richard M. Goldberg, Stephen N. Thibodeau, Suresh G. Nair, Garth D. Nelson, Michelle R. Mahoney, Steven R. Alberts, Qian Shi, David Tougeron, Harry H. Yoon
PDF file - 81KB, Table S1. Multivariable logistic regression models showing the association of clinicopathologic and molecular characteristics with KRAS codon 12 or 13 mutation status in 2,478 BRAF-wild type stage III colon cancers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ee6b4b974c62a8abe876a46c3ed89ef
https://doi.org/10.1158/1078-0432.22454807.v1
https://doi.org/10.1158/1078-0432.22454807.v1
Autor:
Tatjana Kolevska, Martin R. Weiser, Bryce B. Reeve, Narre Heon, Jeffrey P. Meyers, Deborah Schrag, Andrea Denicoff, Jennifer K. Wind, Harvey J. Mamon, Garth D. Nelson, Lori M. Minasian, Amylou C. Dueck, Mary C. Shaw, Brenda Ginos, Sandra A. Mitchell, Qian Shi, Lauren J. Rogak, George J. Chang, Deborah Watkins Bruner, Ethan Basch
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Purpose The US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed to enable patient reporting of symptomatic adverse events in oncology clinical research.
Autor:
Steven R. Alberts, Amanda I. Phipps, Paul J. Limburg, Richard M. Goldberg, Anthony F. Shields, Polly A. Newcomb, Garth D. Nelson, Daniel J. Sargent, Morton S. Kahlenberg, Qian Shi, Frank A. Sinicrope, Suresh G. Nair Md, Sharlene Gill, Emily Chan
Publikováno v:
International Journal of Cancer. 139:986-995
Alcohol consumption is associated with a modest increased risk of colon cancer, but its relationship with colon cancer survival has not been elucidated. Using data from a phase III randomized adjuvant trial, we assessed the association of alcohol con
Autor:
Stephen N. Thibodeau, Michelle R. Mahoney, Richard M. Goldberg, Harry H. Yoon, Daniel J. Sargent, Thomas C. Smyrk, Steven R. Alberts, Frank A. Sinicrope, Garth D. Nelson
Publikováno v:
Clinical Cancer Research. 21:5294-5304
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas. Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (ex
Autor:
David J. Inwards, Luis F. Porrata, Ivana N. Micallef, Craig B. Reeder, Randy D. Gascoyne, Betsy LaPlant, Thomas M. Habermann, Patrick B. Johnston, James M. Foran, William R. Macon, Garth D. Nelson, Stephen M. Ansell, Carrie A. Thompson, Thomas E. Witzig, Grzegorz S. Nowakowski, Candido E. Rivera
Publikováno v:
Journal of Clinical Oncology. 33:251-257
Purpose Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednis